Cytokine receptor chain
View Patent ↗Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.
1. A method of reducing an allergen-induced airway hyper responsiveness, or an allergen-induced increase of mucus-containing cells in an airway epithelium, in a mammalian subject, said method comprising
administering to the subject a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65° C. in 0.1×SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4, wherein said polypeptide is administered in an amount sufficient to reduce airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium.
2. The method of claim 1 , wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4.
3. The method of claim 2 , wherein said polypeptide is part of fusion protein.
4. The method of claim 3 , wherein said fusion protein comprises an antibody fragment.
5. The method of claim 1 , wherein said polypeptide is part of a fusion protein.
6. The method of claim 5 , wherein said fusion protein comprises an antibody fragment.
7. The method of claim 6 , wherein said antibody fragment includes an Fc fragment.
8. The method of claim 1 , wherein the allergen-induced increase in airway hyper responsiveness is reduced.
9. The method of claim 1 , wherein the allergen-induced increase in mucus-containing cells in the airway epithelium is reduced.
10. A method of administering a polypeptide to a mammalian subject having allergen-induced airway hyper responsiveness, or allergen-induced increase of mucus-containing cells in an airway epithelium, said method comprising administering a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65° C. in 0.1×SSC to the complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4 in an amount sufficient to decrease airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium, wherein said polypeptide is administered by oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection.
11. The method of claim 10 , wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4.
12. The method of claim 11 , wherein said polypeptide is part of a fusion protein.
13. The method of claim 10 , wherein said polypeptide is part of a fusion protein.
14. The method of claim 13 , wherein said fusion protein comprises an antibody fragment.
15. The method of claim 10 , wherein the subject has increased allergen-induced airway hyper responsiveness.
16. The method of claim 10 , wherein the subject has an increase in allergen-induced mucus-containing cells in the airway epithelium.
17. A method of treating an inflammatory condition of the lung characterized by an increase in allergen-induced airway hyper responsiveness and mucus-containing cells in a mammalian subject said method comprising administering to the subject a therapeutically effective amount of a polypeptide encoded by a polynucleotide that hybridizes under conditions comprising hybridization at 65° C. in 0.1×SSC to complement of the portion of SEQ ID NO:3 that encodes from amino acid 26 to amino acid 341 of SEQ ID NO:4 in an amount sufficient to decrease the lung inflammation in the subject.
18. The method of claim 17 , wherein said polypeptide comprises from amino acid 26 to amino acid 341 of SEQ ID NO:4.
19. The method of claim 18 , wherein said polypeptide is part of a fusion protein.
20. The method of claim 19 , wherein said fusion comprises an antibody fragment.
21. The method of claim 20 , wherein said antibody fragment includes an Fc fragment.
22. The method of any of claim 1 , 10 or 17 , wherein the administration of the polypeptide results in complete reversal of the allergen-induced airway hyper responsiveness.
23. The method of any of claim 1 , 10 or 17 , wherein the administration of the polypeptide results in complete reversal of the allergen-induced increase in mucus-containing cells in the airway epithelium.